Clinical Research Directory

Inclusion Criteria: * 18\~75 years * Pathologically or cytologically proven unresectable esophageal squamous cell carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TNM staging,M1b limited to clavicular or celiac lymph node metastasis) * Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences * ECOG PS score: 0\~1 * NRS2002 score \<3 * Estimated survival time ≥3 months * Normal organ and marrow function as defined below: Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit * Informed consent Exclusion Criteria: * With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc * Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer * Existing active infection such as active tuberculosis and hepatitis * History of myocardial infarction within the past 6 months or history of ventricular arrhythmia * Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness * History of allergic reactions attributed to paclitaxel, albumin or cisplatin * Participation in other clinical trials currently or within 4 weeks of selection * Pregnant or lactating females